The 2014 Updated GOLD Strategy:A Comparison of the Various Scenarios by Wilke, Sarah et al.
 
 
 University of Groningen
The 2014 Updated GOLD Strategy
Wilke, Sarah; Smid, Dionne E; Spruit, Martijn A; Janssen, Daisy J A; Muris, Jean W M; van
der Molen, Thys; van den Akker, Marjan; Jones, Paul W; Wouters, Emiel F M; Franssen, Frits
M E
Published in:
Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundatio
DOI:
10.15326/jcopdf.1.2.2014.0135
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2014
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Wilke, S., Smid, D. E., Spruit, M. A., Janssen, D. J. A., Muris, J. W. M., van der Molen, T., van den Akker,
M., Jones, P. W., Wouters, E. F. M., & Franssen, F. M. E. (2014). The 2014 Updated GOLD Strategy: A
Comparison of the Various Scenarios. Chronic Obstructive Pulmonary Diseases: Journal of the COPD
Foundatio, 1(2), 212-220. https://doi.org/10.15326/jcopdf.1.2.2014.0135
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 26-12-2020
212 2014 Updated GOLD Scenarios
journal.copdfoundation.org   JCOPDF © 2014 Volume 1 • Number 2 • 2014
For personal use only. Permission required for all other uses.
Chronic Obstructive Pulmonary Diseases:
Journal of the COPD Foundation
Original Research
The 2014 Updated GOLD Strategy: A Comparison of the Various 
Scenarios
Sarah Wilke, MSc,*1 Dionne E. Smid, MSc,*1 Martijn A. Spruit, PhD,1 Daisy J. A. Janssen, MD, PhD,1,2 Jean W. 
M. Muris, MD, PhD,3 Thys van der Molen, MD, PhD,4 Marjan van den Akker, PhD,3,5 Paul W. Jones, MD, PhD,6 
Emiel F.M. Wouters, MD, PhD,1,7 and Frits M.E. Franssen, MD, PhD1
* Joint first author
Background: The 2014 updated Global initiative for chronic Obstructive Lung Disease (GOLD) strategy added 
the St. George’s Respiratory Questionnaire (SGRQ) as the fourth possible symptoms measure. The impact of the 
suggested tools for symptoms of COPD and the different definitions of future risk on the frequency distribution 
and clinical characteristics of the GOLD groups remain unknown.
Methods: Demographic and clinical characteristics were assessed in 542 patients with COPD (57.7% male, age 
64.6 [9.0] years, FEV1 54.7 [22.3]% predicted). Health status was assessed by the COPD-specific SGRQ and 
symptoms of anxiety and depression by the Hospital Anxiety and Depression Scale, anxiety (HADS-A) and 
depression (HADS-D) subscale. Cohen’s Kappa was used to assess agreement between groups. 
Results: Level of agreement in frequency distribution using the modified Medical Research Council dyspnea 
(mMRC) scale ≥2, COPD Assessment Test (CAT) ≥10, Clinical COPD Questionnaire (CCQ) ≥1 and SGRQ ≥25 
was moderate to very good. Best agreement was reached between CCQ and SGRQ (K = 0.838 or 0.851, p<0.001). 
Patients classified in mMRC GOLD A reported higher SGRQ scores, higher HADS-A and HADS-D scores 
compared to patients classified in CAT GOLD A or SGRQ GOLD A. Outcomes were comparable between the risk 
assessment groups. 
Conclusions: Choice of the symptom measure impacts GOLD groups more than choice of the exacerbation risk 
assessment. Health care professionals should be aware that patients are heterogeneous in terms of health status 
and symptoms of anxiety and depression based on the symptom measure used.
Abbreviations: Global initiative for chronic Obstructive Lung Disease, GOLD; St. George’s Respiratory Questionnaire, SGRQ; Hospital 
Anxiety and Depression Scale, anxiety subscale, HADS-A; Hospital Anxiety and Depression Scale, depression subscale, HADS-D; COPD 
Assessment Test, CAT;  Clinical COPD Questionnaire, CCQ; modified Medical Research Council dyspnea scale, mMRC; body mass index, 
BMI; forced expiratory volume in 1 second, FEV1; forced vital capacity, FVC; Timed Up and Go test, TUG test; COPD-specific version of St. 
George’s Respiratory Questionaire, SGRQ-C; least significance difference, LSD.
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Introduction
The 2007 Global initiative for chronic Obstructive Lung 
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into 4 groups (GOLD stages I to IV), based on the 
degree of airflow limitation.1 This parameter, however, 
is only poorly-to-moderately associated with disease 
activity and progression, extra-pulmonary features and 
comorbidities, and prognosis in COPD patients.2-4 
Therefore, the 2011 GOLD strategy started classifying 
patients in 4 new groups (GOLD groups A to D) based 
on the combination of the degree of airflow limitation 
and the number of exacerbations in the past 12 months 
(A/B vs. C/D); and the severity of symptoms (A/C vs. 
B/D) (Table 1). To assess the severity of symptoms, the 
GOLD strategy recommends new, simple and reliable 
assessment tools, designed for use in routine daily 
clinical practice.5
Jones and colleagues6 were the first to study the 
impact of the choice of symptom measure (modified 
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Medical Research Council dyspnea [mMRC] scale 
or COPD Assessment Test [CAT]) on the frequency 
distribution and clinical characteristics of the GOLD 
groups. The current mMRC cut-point of grade ≥2 
did not match with the current CAT cut-point of ≥10 
points.6  Thus, the choice of symptom measure clearly 
influences the new GOLD classification, 6,7 and in turn, 
the necessity for refinement of the current mMRC and/
or CAT cut-points was suggested.
The 2013 GOLD strategy added the Clinical COPD 
Questionnaire (CCQ) as the third possibility to classify 
patients to the low (A/C) or high (B/D) symptom group. 
Moreover, the number of COPD hospitalizations in 
the past 12 months (cut-point: ≥1 hospitalizations) 
was added as the third criterion to classify patients as 
GOLD low (A/B) or high (C/D) risk.8 Casanova and 
colleagues9 showed that the symptom measure (i.e. 
mMRC, CAT or CCQ) used “can substantially alter 
group assignment.” Since the St. George’s Respiratory 
Questionnaire (SGRQ) is the most documented measure 
and commonly used in COPD studies, the 2014 updated 
GOLD strategy added the SGRQ (cut-point: ≥25 points) 
as a fourth possibility to grade symptoms.10 To date, the 
impact of all of these introduced assessment tools on 
the frequency distribution and clinical characteristics 
of the GOLD groups remain unknown. Therefore, the 
aims of the present study were: 1) to investigate the 
impact of the 4 different assessment tools for symptoms 
(mMRC, CAT, CCQ or SGRQ) and different definitions 
of future risk (degree of airflow limitation/≥2 COPD 
exacerbations, and degree of airflow limitation/≥1 
hospitalization for COPD exacerbation) on the 
frequency distribution of GOLD groups A to D; and  2) 
to study differences in health status, functional mobility, 
symptoms of anxiety and depression, and self-reported 
comorbidities between the GOLD groups using these 
different scenarios. We hypothesized a priori that the 
symptom measures impact the GOLD distribution as 
well as the clinical characteristics of the GOLD groups.
Methods
Design
The current cross-sectional analyses are part of an 
ongoing prospective observational study about 
determinants of health status assessed with CAT in a 
broad sample of COPD patients. The Medical Ethical 
Committee of the Maastricht University Medical 
Centre+ Maastricht, the Netherlands (METC 11-3-070) 
approved this study, which was registered at the Dutch 
Trial Register (NTR 3416).
Study Population
Patients were eligible to participate if they had a primary 
diagnosis of COPD and if they were clinically stable for 
at least 4 weeks preceding enrollment. Patients were 
excluded if they had a history of other lung diseases, had 
undergone lung surgery or had a malignancy within the 
last 5 years. All patients gave written informed consent.
     Patients were recruited in primary, secondary and 
tertiary care settings between April 2012 and April 
2014. Primary care patients only received treatment by 
their general practitioner and never contacted a chest 
physician or were previously treated in tertiary care. 
Secondary care patients were only treated by a chest 
physician but were not previously treated in tertiary 
care. Primary and secondary care patients were recruited 
through general practitioner practices selected from 
the Registration Network of Family Practices, RNH.11 
Tertiary care patients were recruited at CIRO+, a center 
for pulmonary rehabilitation in Horn, the Netherlands, 
during their pre-rehabilitation assessment.  
Measurements
Primary and secondary care patients were assessed 
during home visits, while tertiary care patients were 
measured during an inpatient pre-rehabilitation 
assessment.12 Demographics, body mass index 
(BMI), smoking status, number of exacerbations 
and hospitalizations during the last 12 months, use 
of long-term oxygen therapy, current medication, 
post-bronchodilator spirometry (forced expiratory 
volume in 1 second, [FEV1], and forced vital capacity, 
[FVC]), mMRC dyspnea grade,13 functional mobility 
(Timed Up and Go [TUG] test)14 and self-reported 
comorbidities (Charlson Comorbidity Index)15 were 
assessed. Symptoms of anxiety and depression were 
assessed by using the Hospital Anxiety and Depression 
Scale, consisting of an anxiety subscale (HADS-A) 
and depression subscale (HADS-D).16,17 In addition, 
disease-specific health status was assessed using the 
CAT,18 the CCQ19 and the COPD-specific version 
of the SGRQ (SGRQ-C).20 SGRQ scores were used to 
assess differences in health status between the various 
scenarios.
Statistics
Allocation to GOLD groups was made using mMRC 
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≥2 vs. CAT ≥10 or CCQ ≥1 or SGRQ ≥25 and degree 
of airflow limitation/≥2 exacerbations vs. degree of 
airflow limitation/≥1 hospitalization in the previous 
12 months. Bivariate correlations (Pearson’s product-
moment correlation) between mMRC, CAT, CCQ 
and SGRQ scores were assessed. Cohen’s Kappa was 
used to assess agreement between the frequencies of 
patients classified into GOLD groups A to D using the 
different cut-points. Kappa values were categorized as 
having poor (<0.0), slight (0.00-0.20), fair (0.21-0.40), 
moderate (0.41-0.60), substantial (0.61-0.80), and very 
good (0.81-1.00) agreement.21 Patient characteristics 
were compared between GOLD groups A to D using 
univariate analysis of variance for continuous variables, 
followed by post hoc least significance difference 
(LSD) multiple comparisons, or Kruskal-Wallis test 
followed by Mann-Whitney U test, as appropriate. 
Categorical variables were compared using Chi-
Square tests. The same statistics were used to compare 
patient characteristics and health status, symptoms of 
anxiety and depression, the TUG test, and self-reported 
comorbidities between GOLD groups. For other tests, 
the independent sample t-test or Mann-Whitney U test 
were used, as appropriate. All statistical analyses were 
performed using SPSS for Windows, Version 19.0. A 
p-value ≤0.01 was interpreted as statistically significant.
Results
Patient Characteristics
In total, 542 patients with 
moderate to very severe 
COPD were included. 
Characteristics of the study 
population are presented in 
Table 2.
The Impact of Symptom 
Measure on Frequency 
Distribution
The mMRC, CAT, CCQ 
and SGRQ scores were 
moderately to strongly 
correlated, with the best 
relationship being between 
the CCQ and SGRQ (r = 
0.853, p < 0.001) (e-Figure 
1). Using the cut-points 
selected, the majority of 
the patients were classified Frequency distribution stratified by symptom measure and exacerbation risk assessment.
as GOLD D, irrespective of the symptom measure used (Figure 1).  The agreement of classification (Kappa 
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patients, with worst (=highest) health status scores in 
GOLD D groups (Figure 2, e-Table 1a and e-Table 1b). 
mMRC GOLD A patients had a significantly worse 
health status compared to CAT GOLD A, CCQ GOLD 
A and SGRQ GOLD A patients. mMRC GOLD B, 
CCQ GOLD B and SGRQ GOLD B patients reported 
significantly worse health status compared to CAT 
GOLD B patients. In GOLD C and D groups, however, 
mean SGRQ scores were comparable between the 
symptom measures mMRC, CAT and CCQ. mMRC 
GOLD C and CAT GOLD C patients reported worse 
health status compared to SGRQ GOLD C patients 
(Figure 2). On average, GOLD B/D patients needed 
more time to complete the TUG test compared to 
GOLD A/C patients, with worst impairment in GOLD 
D patients. mMRC GOLD B patients and SGRQ GOLD 
B patients reported more comorbidities compared to 
mMRC GOLD A, C and D patients and SGRQ A and D 
patients, respectively (e-Table 1a and e-Table1b). There 
were no differences in the number of self-reported 
comorbidities and time needed to complete the TUG 
test between GOLD groups using mMRC, CAT, CCQ or 
SGRQ (Figure 2).
a) SGRQ, b) symptoms of anxiety (HADS-A) c) depression 
(HADS-D), d) functional mobility (TUG test) and e) self-reported 
comorbidities (Charlson Comorbidity Index) stratified by symptom 
measure and exacerbation risk assessment (left column: degree 
of airflow limitation/exacerbation history; right column: degree of 
airflow limitation/hospitalization history). Significances are only 
described for comparison between similar GOLD groups using 
different symptom measures (e.g. mMRC GOLD A vs. CAT GOLD A 
vs. CCQ GOLD A vs. SGRQ GOLD A. For significances within each 
symptom measure please see online supplementary e-Table 1a and 
e-Table 1b).  *p≤0.01 vs. CAT; #p≤0.01 vs. CCQ; §p≤0.01 vs. SGRQ
The Impact of Symptom Measure on Clinical 
Characteristics
On average, GOLD B/D patients had worse disease-
specific health status scores compared to GOLD  A/C 
values) into low (A/C) or high (B/D) symptom GOLD 
groups using the mMRC, CAT, CCQ or SGRQ scores 
is summarized in Table 3.  There was a moderate to 
substantial agreement (K = 0.602 or 0.626, p < 0.001) 
between mMRC and CAT and very good agreement (K 
= 0.838 or 0.851, p < 0.001) between CCQ and SGRQ 
scores.
On average, GOLD B/D patients reported significantly 
higher HADS-A and HADS-D scores compared to 
GOLD A/C patients (e-Table 1a and e-Table 1b). mMRC
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GOLD A patients had higher (=worse) HADS-A and 
HADS-D scores compared to CAT GOLD A and SGRQ 
GOLD A patients. 
The Impact of Exacerbation Risk Assessment 
on Frequency Distribution
Table 4  shows that there is substantial agreement 
between the classifications using the exacerbation 
history and hospitalization history as risk assessment.
The Impact of Exacerbation Risk Assessment 
on Clinical Characteristics
In general, the impact of choice of symptom cut-point 
measure on demographic and clinical characteristics 
was similar for both exacerbation risk assessment 
groups (Figure 2, e-Table 1a and e-Table 1b).  Health 
status, physical mobility, symptoms of anxiety and 
depression and self-reported comorbidities were 




This is the first study investigating the impact of the 
4 GOLD-recommended symptom measures (mMRC, 
CAT, CCQ and SGRQ) and the 2 measures for 
exacerbation risk (exacerbation and hospitalization 
history) on the frequency distribution of GOLD groups 
A to D, and their clinical characteristics in COPD 
patients. It shows that the choice of symptom measure 
influences the frequency distribution of the new GOLD 
groups more than the measures for exacerbation risk. 
Moreover, health status and psychological symptoms 
differ between different outcome measures used to 
identify high and low symptom patients, in particular 
in GOLD groups A and B. Thus, our hypothesis that the 
symptom measures impact the GOLD distribution as 
well as the clinical characteristics of the GOLD groups 
is partly confirmed.
The Impact of Symptom Measure on Frequency 
Distribution
The distribution of patients between GOLD groups 
A/C or B/D was dependent on the choice of symptom 
measure. As suggested before,6 this is not surprising 
since CAT, CCQ and SGRQ cover a broad variety 
of symptoms and have been developed differently 
compared to mMRC.18,19 The current study extends 
previous reports6,22 and shows that the mMRC cut-
point of ≥2 gives an overrepresentation of patients 
classified in groups A and C compared with cut-points of 
the CAT, CCQ and SGRQ. In addition, previous studies 
only included primary and secondary care patients,22,23 
while the majority of patients in the current analyses 
were recruited in tertiary care. As suggested before,23 
the distribution of patients across GOLD groups seems 
to differ by sample population. The results also show 
that the impact of the choice of symptom measure is 
most pronounced in the low risk groups GOLD A/B. 
Probably, the impact of severe airflow limitation or 
exacerbations/hospitalizations on health status is 
more pronounced in the high-risk groups GOLD C/D, 
compared to the low-risk groups GOLD A/B, which may 
overwhelm the impact of choice of symptom measure 
in the high-risk groups. The current study found a 
similar degree of agreement between mMRC and CAT 
compared to previous studies6,9,22 and showed even a 
better agreement between mMRC-CCQ and CAT-CCQ 
with best agreement between CCQ-SGRQ. However, 
the current study extends previous findings24 showing 
a similarly strong relationship between CAT and CCQ 
(r = 0.771, p < 0.001) and the best relationship between 
CCQ and SGRQ (r= 0.853, p < 0.001) (e-Figure 1).
     Patients with a CAT score ≥10 points experience a 
negative impact of their disease on their daily lives.25 
Jones and colleagues6 showed that the classification of 
low symptom patients were approximately equivalent 
using the cut-points of mMRC grade ≥1 and CAT 
score ≥10. Other studies suggest a CAT cut-point of 
22 points23 or 13 points26 to determine low symptom 
groups which correspond with an mMRC cut-point 
of 2 or more. However, the choice of an adequate cut-
point remains debatable: the updated GOLD 2014 
guidelines suggest a cut-point for the CCQ between 
1.0-1.5 points9 while the current study suggests a 
CCQ cut-point of ≥0.6 points and an mMRC grade 
of ≥1 matching with a CAT cut-point of ≥10 points 
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to reach the best agreement (e-Figure 2 and e-Figure 
3). The classification is important since treatment is 
recommended according to the classification of the 
disease described in the GOLD guidelines. Although, 
the CAT and CCQ are both useful tools to assess 
patients’ experience of COPD, 24 it has been suggested 
to be challenging using both tools in clinical practice.27 
Kim and colleagues22 suggested using the worse score 
on CAT or mMRC to allocate patients to GOLD groups 
A/C or B/D, like the procedure for exacerbation risk 
assessment. However, if this procedure is applied in the 
current study, only 4.8% of all patients are classified in 
GOLD groups A/C of which most of them are classified 
in the low risk group A. Therefore, this procedure 
probably gives an underestimation of low symptom 
patients (GOLD A/C). 
The Impact of Symptom Measure on Clinical 
Characteristics
Furthermore, the current study shows that patients 
classified as GOLD group A/C using mMRC reported 
a worse health status as compared to CAT or CCQ 
assessed patients. This supports and extends previous 
findings.6 Interestingly, in mMRC GOLD B, CCQ GOLD 
B and SGRQ GOLD B groups, patients reported a worse 
health status compared with CAT GOLD B patients. 
Furthermore, mMRC GOLD A patients reported higher 
HADS-A and HADS-D scores compared to CAT GOLD 
A and SGRQ GOLD A patients. Previously, dyspnea 
and CAT scores have been associated with symptoms 
of anxiety and depression.28-30 Since mMRC GOLD A 
patients reported worse health status scores (Figure 2, 
e-Table 1a and e-Table 1b), it is reasonable that those 
patients also report higher HADS scores.
     The current study identified significantly more self-
reported comorbidities in mMRC GOLD B and SGRQ 
GOLD B/C compared to mMRC GOLD A, C and D 
and SGRQ A or D patients, respectively, while there 
were no differences in self-reported comorbidities 
between the GOLD groups when using the alternative 
GOLD-recommended symptom measures. Although 
previous studies also showed the highest prevalence 
of comorbidities in GOLD B,31,32 the present results 
once again emphasize the importance of the choice 
of symptom measure. In addition, these studies only 
used the mMRC to categorize symptoms31,32 while the 
current study considered all various scenarios.
     Finally, the choice of risk assessment did not impact 
the frequency distribution or the clinical characteristics 
which is in line with a recently published report23 
suggesting a 4.2% shift from low risk patients to high 
risk patients, independent of the symptom measure 
used. While the authors concluded that the meaning 
was clinically uncertain,23 the present study indicates 
that both measures for risk assessment are comparable. 
Limitations
There are a number of aspects that need to be taken 
into consideration regarding the current study. The 
proportion of patients from primary (11.6%), secondary 
(17.9%) and tertiary (70.5%) care is not equally 
distributed, which may limit the external validity of 
the current findings. Furthermore, the current findings 
need to be interpreted in the light of the number of 
comparisons that were made in the present study.33 
Nonetheless, multiple findings in the same direction, 
rather than a single statistically significant result, 
suggest that these are not due to chance alone. Future 
studies are necessary to further assess the impact of the 
use of mMRC, CAT, CCQ and SGRQ on prognosis in 
all groups and to provide recommendations for disease 
management.
Conclusion
In contrast to the possibilities to assess future risk, the 
4 possible symptom measures have an impact upon 
the distribution of patients between the new GOLD 
groups. This is especially seen in the low-risk GOLD 
groups A and B, in terms of impact on health status 
and psychological symptoms. Health care professionals 
should be aware that patients differ in terms of health 
status and symptoms of anxiety and depression based 
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